A recent study has revealed a significant and persistent increase in antidepressant usage in France since the onset of the Covid pandemic. Researchers from the Universities of Versailles and Zurich conducted the study, which examined prescription trends from 2012 to 2022 with a focus on the pandemic’s effects. The findings, published in the journal BMJ Mental Health, highlight a worrying trend in mental health treatment, raising concerns about the long-term effects of the pandemic on public mental health.
Before the pandemic, antidepressant prescriptions in France were gradually increasing, with a steady rise of 0.02 defined daily doses per 1,000 inhabitants per day (DDD/TID) each month from 2012 to 2019. This increase reflected a growing prevalence of depression and anxiety in the population, attributed to factors such as ageing and changing societal pressures. However, the onset of the pandemic in early 2020 brought about a dramatic shift in this trend.
According to the study, antidepressant sales surged by 0.20 DDD/TID per month from May 2020 onwards, marking a significant departure from the pre-pandemic trajectory. This escalation resulted in an estimated excess of 112.6 DDD/TID by December 2022, a figure that far exceeds what would have been expected based on pre-pandemic trends. The most commonly prescribed antidepressants during this period were escitalopram, fluoxetine, paroxetine, sertraline, and venlafaxine.
While the increase in antidepressant prescriptions was stark, the trend for anxiolytics – drugs used to treat anxiety – was somewhat different. Anxiolytic sales, which had been declining steadily before the pandemic, saw a temporary spike in early 2020. But this increase was short-lived, with sales returning to expected levels by the end of 2022. The researchers estimated an excess of 33.8 DDD/TID for anxiolytics during the pandemic, a notable but less dramatic rise compared to antidepressants.
According to the study’s authors, a number of factors that the pandemic has made worse may be responsible for the prolonged increase in antidepressant usage. These include the widespread disruption to daily life, the stress and anxiety caused by lockdowns and social isolation, and the challenges faced by the healthcare system, which saw a surge in demand for mental health services. The pandemic also likely led to more individuals seeking treatment for previously undiagnosed conditions, as well as an increase in the severity of existing mental health issues.
Interestingly, the study found no clear correlation between the stringency of pandemic mitigation measures and the increase in antidepressant and anxiolytic prescriptions. This suggests that the rise in medication usage was driven by broader societal impacts of the pandemic rather than specific public health policies.
The findings of this study have significant implications for public health policy in France. The sustained increase in antidepressant prescriptions highlights the need for a robust response to the growing mental health crisis. Researchers and policymakers are urged to consider the long-term consequences of the pandemic on mental health and to ensure that adequate resources are allocated to support those affected.
